(UroToday.com) In this presentation, Dr. Srikala Sridhar discussed results from the Phase 2 NORSE study of erdafitinib or erdafitinib plus cetrelimab in patients with metastatic or locally advanced urothelial carcinoma (UC) and fibroblast growth factor receptor (FGFR) alterations. This study addresses a significant unmet clinical need for better first-line therapy options for patients with metastatic UC who are not eligible for cisplatin-based therapy.